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Accepted 16 December 2014Interest in surgical and non-surgical cosmetic procedures has increased signiﬁcantly over the last few decades.
Billions of dollars are spent on these procedures annually. Although the associated risk is generally low, multiple
cases of skin and soft tissue infections have been reported. Nontuberculous mycobacteria (NTM), in particular
M. chelonae, M. fortuitum, andM. abscessus, have been increasingly identiﬁed as causative of numerous cosmetic
procedure–related infections worldwide. This has therefore become a public health concern. Delays in diagnosis
and appropriate managementmay occur given subtleties in diagnostic methods. The purpose of this review is to
highlight theNTM-related skin and soft tissue infections associatedwithmore common cosmetic procedures, de-
scribe methods of identiﬁcation, and outline best treatment practices.
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The nontuberculous mycobacteria (NTM) represent an emerging
and increasingly recognized etiology of skin and soft tissue infections
associated with injections and minor surgical procedures in the United
States. Because these organisms require laboratory techniques other
than the standard gram stain with aerobic and anaerobic culture and
sensitivity for identiﬁcation, and tend not to respond to courses of
typical antibacterial agents effective against streptococci and staphylo-
cocci, delay in diagnosis and appropriate antimicrobial management
may occur. The purpose of this review is to highlight the typical
mycobacteria that are causative of infections associatedwithmore com-
mon cosmetic procedures, and to describemethods of identiﬁcation and
best treatment practices.Epidemiology
The NTM group of organisms consists of more than 125 species, de-
ﬁned as mycobacteria species other than M. tuberculosis andM. leprae.
These organisms are found worldwide and are ubiquitous in the envi-
ronment. Tap water is the primary reservoir for human transmission,
but NTM are also found in soil, animals, vegetable matter, and birds
(Mandell et al., 2009). NTM-related infections are acquired through en-
vironmental exposures. There have been no documented cases of
human-to-human or animal-to-human transmission. An abnormal im-
mune system, involving, for example, a decline in CD4+ T cell countn behalf of Women's Dermatologic Soormacrophage dysfunction, is prone toNTM infection. Similar to other in-
tracellular pathogens, NTM are phagocytized and killed by normal func-
tioning macrophages in response to IFN- production, up-regulated by
interleukin-12 (IL-12). As such, deﬁciencies or abnormalities in this posi-
tive feedback loop, acquired or genetic, increase the risk of NTM infections
(Grifﬁth et al., 2007). Tumor necrosis factorα (TNF) plays a critical role in
control of infection by intracellular organisms, as evidenced by well-
documented risk of reactivation tuberculosis in patients receiving TNF in-
hibitor therapy (Keane, 2004). IFN- and IL-12 control mycobacteria
through the up-regulation TNF α, made predominantly by monocytes/
macrophages. An increased risk ofNTM infections is therefore theoretical-
ly plausible during TNF inhibitor therapy, and most experts recommend
treating and controlling known NTM infections in this setting.
The most common clinical manifestations of NTM infection in the
United States include pulmonary disease, lymphatic disease, skin and
soft tissue infections, and disseminated disease. Mycobacterium avium
complex (MAC),M. fortuitum, andM. kansasii are themost common iso-
lates in the US, with reports of all three most common in the Southeast-
ern United States (Grifﬁth et al., 2007). The incidence of NTM infections
related to cosmetic procedures is on the rise and increasingly becoming
a public health concern. NTM have been recently implicated in skin and
soft tissue infections followingpedicure,mesotherapy, laser resurfacing,
breast augmentation, tattoos, implants and ﬁllers, body piercings, lipo-
suction, Mohs micrographic surgery, punch biopsies, and injections.
Microbiology
Mycobacteria are aerobic, non-motile, acid-fast bacilli, in that they
have the ability to retain dyes after washing of alcohol decolorization.
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mycobacteria (RGM) with subsets of pigmented and nonpigmented or-
ganisms, which form mature colonies on culture in less than 7 days;
(2) slow-growing mycobacteria with subsets of nonchromogens (do
not produce pigment), scotochromogens (produce pigment in the ab-
sence of light) and photochromogens (produce yellow pigment with
light exposure), which form mature colonies on culture in more than
7 days (Table 1). We will focus primarily on the organisms that most
commonly cause skin and soft tissue infections in the United States:
M. abscessus,M. fortuitum andM. chelonae.
In terms of specimen collection for laboratory evaluation, potential
sources of contamination, such as tapwater, should be avoided, because
environmental mycobacteria may be present. Aseptic collection of as
much ﬂuid as possible by needle aspiration or surgical procedures is rec-
ommended. Swabs are not recommended for sample collection because
they often result in limited culture material, decreasing chances for re-
covery of NTM. The recommended method for staining clinical speci-
mens is the ﬂuorochrome technique. The Gram stain will not reliably
detect mycobacteria. In many cases, the NTM, especially the RGM, may
be more sensitive to the AFB decolorization procedure and may not
stain at all with ﬂuorochrome stains, so negative smears do not necessar-
ily mean that NTM, especially RGM, are not present in a clinical sample
(Grifﬁth et al., 2007). Histopathology of tissue specimens obtained
from skin biopsy may yield additional helpful information, as certain
morphological characteristics, such as granulomatous changes,
lymphohistiocytic inﬁltrate, as well as special stains for AFBmay indicate
mycobacterial infection. However, culture would still be necessary to
identify a speciﬁc organism and determine speciﬁc antimicrobial suscep-
tibility (see below) (Drage et al., 2010).
The optimal temperature formost cultures for NTM is between 28 and
37°Cwith rare exception (M. haemophilum,M. ulcerans). Cultures for RGM
andM.marinum should be incubated at 28 to 30°C. All skin, jointﬂuid, and
bone specimens should be cultured at 28 to 30°C and at 35 to 37°C
(Tortoli, 2003). Most NTM grow within 2 to 3 weeks on subculture.
Clinical Manifestations
There has been a signiﬁcant surge in popularity of cosmetic proce-
dures in recent years. According to the American Society for Aesthetic
Plastic Surgery (http://www.surgery.org/), in 2011 alone, approximate-
ly 9 million non-surgical and surgical cosmetic procedures, most com-
monly botulinum toxin and liposuction (2.6 million and 325,332
procedures, respectively) were performed. The reported increased inci-
dence of cutaneous NTM infections over the last few decades is likely to
be associated with higher demand for and more frequent performance
of cosmetic procedures (Wentworth et al., 2013). RGM, in particular
M. chelonae, M. fortuitum andM. abscessus have been commonly report-
ed as causative of skin and soft tissue infections (SSTIs) related to non-
surgical cosmetic procedures including tattoos, permanent eyebrow
makeup, dermal ﬁllers, laser resurfacing and mesotherapy. Infections
related to surgical cosmetic procedures such as liposuction, breast aug-
mentation, Mohs surgery, and facelifts have also been reported, as well
as pedicure and foot bath related infections.Table 1
Microbiological classiﬁcation of NTM. Adapted fromMandell, Douglas and Bennett’s: Principles
Rapid Growing Mycobacteria Slow Growin
Pigmented Non-pigmented Photochromo
M. abscessus M. mageritense M. kansasii
M. chelonae M. wolkinsky M. marinum
M. fortuitum
M. mucogenicum
M. smegmatis
(NTM, Nontuberculous mycobacteria).Permanent tattoos are created by intradermal injection of imperish-
able ink, which is dispersed throughout the epidermis and upper der-
mis. The manipulation of the skin barrier and the presence of pigment
activate the immune system to phagocytize the pigment, producing
the image. Tattoos have become increasingly popular in recent years
worldwide. The number of adults with one or more tattoos in the US
has increased from 14% in 2008 to 21% in 2012 (LeBlanc et al., 2012).
Multiple reports across Western Europe, Australia, and the US of NTM
have surfaced as causes of tattoo-associated skin and soft tissue infec-
tions (Atkins andGottlieb, 2014),which has prompted numerous inves-
tigations by the Food and Drug Administration (FDA). One of the ﬁrst
such reports, published online in 2009, documents an outbreak of
M. chelonae in 6 patients who had received tattoos at a single establish-
ment; diagnosis of NTM was delayed in all 6 cases, and no clear source
was identiﬁed (inks, soaps, water were culture negative) (Drage et al.,
2010). In January 2012, 19 individuals were reported in Rochester,
New York, who presented with persistent red papules on the gray
areas of tattoos within 3 weeks of acquiring the tattoo (Kennedy et al.,
2012). There were 14 conﬁrmed cases of M. chelonae tattoo associated
infections in Monroe County New York and 1 conﬁrmed case of
M. abscessus tattoo associated infection reported in Colorado (Centers
for Disease Control and Prevention, 2012). The FDA investigated many
of these reported cases and discovered that the inks contained
mycobacteria, contaminated during manufacturing of black or grey
inks or when the inks were diluted with tap water. The fact that tattoo
artists and establishments inmany communities are not subject toman-
datory health inspections and that the ink and tattoo equipment do not
require FDA approval, may contribute to the increase in the incidence of
tattoo related SSTIs. The CDC now recommends that all tattoo inks to be
manufactured or diluted with sterile water only.
Permanent eyebrow makeup involves multiple injections of pigment
into the dermis. Twelve cases ofM. haemophilum-associated skin lesions
of the eyebrows and ipsilateral cervical lymphadenopathy associated
with permanent eyebrow makeup procedure were reported in
Switzerland in 2009 (Giulieri et al., 2011). In addition,M. haemophilum
was conﬁrmed as the causative organism in 2 patients who presented
with nodular lesions of the eyebrows where permanent makeup had
been applied (Wollina, 2011).
Injection of dermal ﬁllers such as silicone, collagen, and hyaluronic
acid into the face has become increasingly popular to decrease the ap-
pearance of wrinkles. The ﬁrst 3 cases ofM. chelonae skin and soft tissue
infections associated with dermal injections were conﬁrmed in Oregon
in 2008. The clinic's water supplywas identiﬁed as the source of the iso-
lates (Rodriguez et al., 2013).
Laser resurfacing is an modality used to reﬁne and rejuvenate the
skin. One case report describes the development of multiple erythema-
tous papules and pustules diffusely over the face, neck, and chest 2
weeks after undergoing laser resurfacing. M. abscessus was implicated
(Culton et al., 2013). In another reported case, the patient developed
painful pustular lesions on her neck 9 days after the procedure, and
M. chelonaewas identiﬁed (Culton et al., 2013).
Mesotherapy is a technique that involves injection of plant extracts,
homeopathic agents, pharmaceuticals, vitamins, and other bioactiveand Practice of Infectious Diseases, pages 2844–50 (Mandell et al., 2009).
g Mycobacteria
gens Scotochromogens Nonchromogens
M. gordonae M. avium complex
M. scrofulaceum M. haemophilum
M. malmoense
M. simiae
M. szulgai
M. ulcerans
M. xenopi
Table 2
Toxicities of primary agents used to treat NTM infections (Grifﬁth et al., 2007).
Drug Toxicities
Clarithromycin Nausea, vomiting, diarrhea⁎, hepatitis, many drug interactions
Ciproﬂoxacin/moxiﬂoxacin Nausea, vomiting, diarrhea⁎, headache, insomnia, tendonitis
Amikacin/tobramycin Nephrotoxicity, ototoxicity, dizziness, vertigo, ataxia [monitor serum levels]
Rifampin/rifabutin Orange discoloration of secretions, nausea, vomiting, hypersensitivity reaction, hepatitis, cytopenias, multiple drug interactions
Cefoxitin Hypersensitivity, cytopenias, diarrhea⁎
Imipenem Nausea, vomiting, diarrhea⁎, hypersensitivity, seizure, confusion, hepatitis, cytopenias
Tetracyclines Nausea, vomiting, diarrhea⁎, photosensitivity, rash, dizziness, vertigo, pseudotumor cerebri
Sulfonamides Nausea, vomiting, diarrhea⁎, cytopenias, hypersensitivity
Linezolid Cytopenias, peripheral neuropathy, nausea, vomiting, diarrhea
Tigecycline Nausea, vomiting, photosensitivity, pseudotumor cerebri, pancreatitis
(NTM, Nontuberculous mycobacteria).
⁎ including Clostridium difﬁcile colitis.
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weight loss and cellulite reduction. NTM infections associated with
mesotherapy have been linked to contaminatedmaterial being injected
by non-physicians (Sanudo et al., 2007). Eleven cases of M. chelonae-
related erythematous, tender, subcutaneous draining nodules at the in-
jection site were reported in 2006–2007 (Regnier et al., 2009). Five
cases of M. chelonae were reported in Colombia during 2004–2005, in
which patients presented with localized skin lesions to the area of
mesotherapy (Sanudo et al., 2007). In 2001, 3 cases were reported be-
cause they developed painful nodules after receiving mesotherapy
caused by M. fortuitum in Spain (Nagore et al., 2001). M. abscessus has
also been implicated in skin infections aftermesotherapy in 17 otherwise
healthy subjects in 2009 in Spain (Galmes-Truyols et al., 2011) and 3 pa-
tients in Thailand in 2011 (Wongkitisophon et al., 2011). In 2005, Virgin-
ia Department of Health and the CDC investigated and outbreak of skin
lesions unresponsive to antimicrobial therapy patients who receive
mesotherapy by a non-licensed practitioner in the District of Columbia.
M. chelonae and M. haemophilum were both identiﬁed as the causative
isolates (Centers for Disease Control and Prevention, 2005).
Liposuction has become a very common surgical cosmetic procedure.
Thirty four cases of cutaneous abscesses within 6months after undergo-
ing liposuction by a single practitioner caused byM. chelonae were re-
ported in 2002 (Meyers et al., 2002). Two cases of M. fortuitum
associated SSTIs presenting with recurrent abscesses following abdomi-
nal plastic surgery and liposuction were reported in France in 2008
(Regnier et al., 2008). Additionally, more recent cases of recurrent ab-
dominal abscesses following abdominoplasty and liposuction have
been reported (Bax et al., 2014; Kim and Mascola, 2010).
A case ofM. abscessus infection presented as multiple erythematous
papules post-Mohs procedure (Fisher and Gloster, 2005). In 2003, the
New Jersey Department of Health and Senior Services investigated 8
cases ofM.chelonae SSTI following facelift procedures (Centers for Dis-
ease Control and Prevention, 2004).M. fortuitum SSTI following a bilat-
eral facelift presenting with a maxillary nodule was also reported
(Angeli et al., 2004). The use of contaminated gentian violet, a marking
solution, has been associated to many surgical site infections following
facelifts and blepharoplasty (Murillo et al., 2000).
Breast augmentations are performed frequently for either cosmetic
or reconstructive purposes (Vinh et al., 2006). Infections following
breast augmentation are rare, with a risk of 1–3% (Feldman et al.,
2009; Heistein et al., 2000). Infections are most commonly due to nor-
mal skin ﬂora and infrequently due to mycobacteria (Heistein et al.,
2000). Cases ofM. fortuitum relatedwound infection post breast implant
placement were described (Lizaso et al., 2011; Vinh et al., 2006). Two
cases of M. fortuitum and 1 case of M. chelonae breast infections after
bilateral reduction mammoplasty were documented (Boettcher
et al., 2010).
Multiple pedicure-associated NTM infection, referred to as furuncu-
losis, most commonly due to RGM, have been registered within the
United States. An outbreak in North Carolina during 2005–2008, involv-
ing 40 cases of pedicure-associated furunculosis due to M. fortuitum,M. abscessus, M. bolletii, and M. chelonae, presenting with pustules,
plaques, nodules, pustules persisting on the lower extremities (Stout
et al., 2011). The outbreak was linked to mycobacteria present in the
bioﬁlm in the foot baths and water intake pipes. A common ﬁnding
identiﬁed among infected individuals was recent shaving of legs prior
to the pedicure. In California during 2000, a large outbreak was identi-
ﬁed, consisting of 110 cases of pedicure-associated furunculosis caused
byM. fortuitum, associated with suboptimal cleaning practices of pedi-
cure foot baths at a single nail salon (Stout et al., 2011).
Therapy
As discussed previously, species identiﬁcation and antimicrobial sus-
ceptibility testing is critical in themanagement of patientswith skin and
soft tissue infections caused by NTM. Degrees of susceptibility to oral
agents vary by NTM species, and prolonged combination therapy is fre-
quently indicated, particularly in cases of severe, deeper seated infec-
tions. For serious skin and soft tissue disease caused by rapid growers,
includingM. abscessus, chelonae, and fortuitum, a minimum of 4 months
of combination therapy is likely necessary, with consideration of longer
durationswhen bone is involved (Grifﬁth et al., 2007). Surgical debride-
ment and removal of infected foreign material should always be pur-
sued in conjunction with antimicrobial therapy when feasible, to
maximize the chances of cure. Speciﬁc therapeutic options are ad-
dressed by NTM species.
Inherently resistant to standard antituberculous agents,M. abscessus
has emerged as one of the most difﬁcult NTM to manage with antimi-
crobial therapy. M. abscessus may also acquire resistance to certain
agents, for example, via induction of the erm gene (erythromycinmeth-
ylase) conferring resistance to macrolides (Atkins and Gottlieb, 2014;
Choi et al., 2012; Grifﬁth et al., 2007). The macrolides are the most reli-
ably active oral agents for the treatment of M. abscessus infections, al-
though increasing consideration is given to oxazolidinones, such as
linezolid, whichmay alsomanifest lowMICs. As such, combination ther-
apy with parenteral agents is usually appropriate, speciﬁcally with
amikacin, the most reliably active parenteral agent, plus one or more
others (Grifﬁth et al., 2007). Other agents with varying degrees of activ-
ity against the organism are cefoxitin and imipenem. It may be reason-
able to deescalate to an oral regimen after initial combination therapy
for several weeks, if there is clear evidence of clinical improvement.
Given relatively high rates of relapse, however, this strategy must be
undertaken with extreme caution (Atkins and Gottlieb, 2014; Regnier
et al., 2009; van Dissel and Kuijper, 2009).
Relatively less resistant to antimicrobials than M. abscessus, M.
chelonae demonstrates frequent susceptibility to clarithromycin,
tobramycin, imipenem, and linezolid, and is uniformly resistant to
cefoxitin. In general, among the aminoglycosides, tobramycin exhibits
more in vitro activity than amikacin (Grifﬁth et al., 2007).M. fortuitum
is generally regarded as less resistant to antimicrobial agents, and there-
fore, easier to treat than other rapid growers. Although appropriate
therapeutic regimens should still be based upon in vitro susceptibility
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both oral and parenteral, including clarithromycin, cefoxitin, imipenem,
amikacin, doxycycline, and trimethoprim/sulfamethoxazole (Lim et al.,
2012). In vitro susceptibility to clarithromycin must be interpreted
with caution, however, given the ability of the M. fortuitum to express
the erm gene (Grifﬁth et al., 2007). Susceptibility data for other species
of NTM, such asM. hemophilum are limited and tend to lack standardi-
zation, making interpretation of results a challenge. This reinforces the
need to obtain minimum inhibitory concentrations for individual clini-
cal isolates to best guide therapeutic choices.
Variability in susceptibilities to antimicrobial agents amongdifferent
NTM species has generated interest in identifying appropriate salvage
regimens for the treatment of these infections. Tigecycline is a
glycylcycline antibiotic with broad spectrum antimicrobial activity
against both gram positive and gram negative organisms. Structurally
related to tetracyclines, it reportedly has good activity against NTM
in vitro (Huang et al., 2013;Wallace et al., 2014). Tigecyclinewas tested
for synergistic effect with clarithromycin and amikacin in isolates of
rapid growers, showing in vitro synergywith clarithromycin and antag-
onismwith amikacin (Huang et al., 2013). A clinical study of 52 patients
with rapid grower NTM infections of the lung and skin/soft tissue/bone
resulted in 48% overall clinical improvementwith tigecycline-based sal-
vage therapy, with signiﬁcant numbers discontinuing prematurely due
to adverse events (Wallace et al., 2014). Toxicities of antimicrobial
agents commonly used to treat NTM infections of the skin and soft tis-
sues are well known and summarized in Table 2.
Conclusions
The last several years havewitnessed a surge inmedical tourism and
interest in cosmetic and aesthetic procedures on a global scale. Taken
together with inconsistent infection control procedures in different
practice settings, these circumstances dictate a heightened awareness
and suspicion for skin and soft tissue infections caused by the NTM.
The complexities and idiosyncrasies in diagnosis and treatment require
communication between specialists in infectious diseases, dermatology,
surgery, and labmedicine, in order to appropriatelymanage these infec-
tions. More stringent regulation and monitoring of procedures and
products labeled as “cosmetics” going forwardwill help reduce baseline
rates of these infections and prevent future outbreaks.
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